Clinical Trial Update: Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating omalizumab in patients with moderate-to-severe persistent allergic asthma not adequately controlled on GINA Step 4 therapy; results wer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Xolair (omalizumab) (omalizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Persistent Allergic Asthma | Phase 3 | Status: COMPLETED | Results posted: 2015-03-23